▟ Vinebot intrinsic value, daily

← back

DHR Danaher Corporation

pharma · valued with opus medium conviction · deep-dived 2026-11-12

SELL
Intrinsic value$105.29
Price (at call)$235.31
Margin of safety -55.3%
vs market (rating basis) -29.3%

A quality consumables franchise in recovery, but the price already assumes peak-like margins return quickly.

The story

Danaher is a razor/razorblade life-sciences tools franchise: bioprocessing consumables (Cytiva, Pall), diagnostics (Beckman, Cepheid, Radiometer) and recurring reagents, held together by the Danaher Business System. The post-COVID destocking slump has ended. TTM revenue is up about 4% to 25.6B and the GAAP operating margin has recovered from 18.3% to 20.2%. It is now a mature compounder in early cyclical recovery, not a growth story, and the acquisition-heavy balance sheet keeps reported returns on capital low.

The recovery is now visible in both revenue and margin, so I nudged year-1 growth up to 6.5% and the target margin to 29%. That margin is near the pre-COVID-normal level after amortization, not the 2021 peak. Sales-to-capital moves from 1.0 to 1.2 (+20%) because organic growth is capital-light: capex of 1.13B is well below D&A of 2.63B. The 0.36 reported figure is inflated by goodwill and should not drive incremental reinvestment. My value still sits well below the price, which tells me the market is pricing a faster, fuller margin snap-back than I can justify at a 5% risk-free rate.

Value drivers

Revenue growth (Y1)6.5%
Terminal growth3.5%
Forecast horizon10y
Target operating margin29.0%
Years to target margin5
Sales-to-capital1.20
Beta0.95
Failure probability1.0%
Cost of capital (WACC)8.9%
Terminal WACC9.1%

Valuation bridge

PV of explicit FCFF40.88B
PV of terminal value49.42B
Equity value74.07B
÷ shares → per share$105.29

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 27.27B 6.5% 22.0% 5.10B 1.39B 3.71B 3.41B
2 28.95B 6.2% 23.7% 5.84B 1.40B 4.44B 3.74B
3 30.64B 5.8% 25.5% 6.64B 1.41B 5.23B 4.05B
4 32.33B 5.5% 27.2% 7.49B 1.40B 6.09B 4.32B
5 34.00B 5.2% 29.0% 8.39B 1.39B 6.99B 4.56B
6 35.64B 4.8% 29.0% 8.79B 1.37B 7.42B 4.44B
7 37.25B 4.5% 29.0% 9.19B 1.34B 7.85B 4.31B
8 38.80B 4.2% 29.0% 9.57B 1.29B 8.28B 4.17B
9 40.29B 3.8% 29.0% 9.94B 1.24B 8.70B 4.02B
10 41.70B 3.5% 29.0% 10.28B 1.17B 9.11B 3.87B

Key risks

  • Bioprocessing recovery stalls as biotech funding and China demand stay weak
  • Margin recovery capped by acquisition amortization, pricing pressure and diagnostics normalization
  • Large, expensive M&A that further dilutes return on capital

Catalysts

  • Sustained bioprocessing order growth and a return to high-single-digit core growth
  • Operating margin re-expanding toward the mid-to-high 20s on volume leverage

History

DatePriceIntrinsicMoSRating
2026-11-12$235.31 $105.29 -55.3% SELL
2026-10-09$217.46 $91.18 -58.1% SELL
2026-09-07$207.66 $47.28 -77.2% STRONG SELL
2026-08-05$194.78 $51.52 -73.5% SELL
2026-07-02$193.72 $58.01 -70.1% SELL
2026-06-23$178.97 $63.98 -64.3% SELL